Abbvie IncChange company Symbol lookupSelect an option...ABBV Abbvie IncAIMC Altra Industrial Motion CorpTRST TrustCo Bank Corp N YVNE Veoneer IncZS Zscaler IncSSTK Shutterstock IncSUI Sun Communities IncSLB Schlumberger NVNWHUF NorthWest Healthcare Properties REITBBI Brickell Biotech IncGo
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
AIMC Altra Industrial Motion Corp
TRST TrustCo Bank Corp N Y
VNE Veoneer Inc
ZS Zscaler Inc
SSTK Shutterstock Inc
SUI Sun Communities Inc
SLB Schlumberger NV
NWHUF NorthWest Healthcare Properties REIT
BBI Brickell Biotech Inc
Health Care : Biotechnology | Large Cap Value
Company profileAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
|
|
|
|
| |
Latest Earnings (Q2 ending 06/2021)
- Q2 Non-GAAP earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
- $3.11
- Q2 Consensus estimate
- $3.09
Latest Earnings Estimate Range
- Highest
estimate - $3.24
- Mean
estimate - $3.09
- Lowest
estimate - $3.04
Quarterly Consensus Estimates and Ranges
ABBV's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.